Immunoprecise Debt to Equity Ratio Trend from 2010 to 2022

IPA
 Stock
  

USD 3.98  0.03  0.76%   

Immunoprecise Antibodies Debt to Equity Ratio is decreasing over the years with slightly volatile fluctuation. Debt to Equity Ratio is expected to dwindle to 0.16. From 2010 to 2022 Immunoprecise Antibodies Debt to Equity Ratio quarterly data regression line had arithmetic mean of 0.50 and r-squared of  0.34. Immunoprecise Antibodies Cost of Revenue is projected to increase significantly based on the last few years of reporting. The past year's Cost of Revenue was at 7.33 Million. The current year Interest Expense is expected to grow to about 596.1 K, whereas Consolidated Income is forecasted to decline to (9.1 M).
  
Refresh
Check Immunoprecise Antibodies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunoprecise main balance sheet or income statement drivers, such as Cost of Revenue of 7.3 M, Gross Profit of 11.8 M or Interest Expense of 596.1 K, as well as many exotic indicators such as Asset Turnover of 0.36, Book Value per Share of 3.25 or Current Ratio of 9.98. Immunoprecise financial statements analysis is a perfect complement when working with Immunoprecise Antibodies Valuation or Volatility modules. It can also supplement various Immunoprecise Antibodies Technical models. Please see the analysis of Immunoprecise Antibodies Correlation against competitors.

Immunoprecise Antibodies Quarterly Debt to Equity Ratio

0.184

Immunoprecise Debt to Equity Ratio Breakdown

Showing smoothed Debt to Equity Ratio of Immunoprecise Antibodies with missing and latest data points interpolated. Measures the ratio between Total Liabilities and Shareholders Equity.Immunoprecise Antibodies' Debt to Equity Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunoprecise Antibodies' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.06 %10 Years Trend
Decreasing
Slightly volatile
 Debt to Equity Ratio 
Share
      Timeline 

Immunoprecise Debt to Equity Ratio Regression Statistics

Arithmetic Mean 0.50
Geometric Mean 0.44
Coefficient Of Variation 40.07
Mean Deviation 0.15
Median 0.57
Standard Deviation 0.20
Sample Variance 0.039907
Range 0.65
R-Value(0.58)
Mean Square Error 0.02872
R-Squared 0.34
Significance 0.036368
Slope(0.029923)
Total Sum of Squares 0.48

Immunoprecise Debt to Equity Ratio History

2019 0.81
2020 0.18
2021 0.16

About Immunoprecise Antibodies Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Immunoprecise Antibodies income statement, its balance sheet, and the statement of cash flows. Immunoprecise Antibodies investors use historical funamental indicators, such as Immunoprecise Antibodies's Debt to Equity Ratio, to determine how well the company is positioned to perform in the future. Although Immunoprecise Antibodies investors may use each financial statement separately, they are all related. The changes in Immunoprecise Antibodies's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immunoprecise Antibodies's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Immunoprecise Antibodies Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Immunoprecise Antibodies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Debt to Equity Ratio 0.16  0.16 
Average Equity40.3 M36.2 M
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada. Immunoprecise Antibodies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people.

Immunoprecise Antibodies Investors Sentiment

The influence of Immunoprecise Antibodies' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Immunoprecise. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Immunoprecise Antibodies Implied Volatility

    
  256.02  
Immunoprecise Antibodies' implied volatility exposes the market's sentiment of Immunoprecise Antibodies stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Immunoprecise Antibodies' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Immunoprecise Antibodies stock will not fluctuate a lot when Immunoprecise Antibodies' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immunoprecise Antibodies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immunoprecise Antibodies' short interest history, or implied volatility extrapolated from Immunoprecise Antibodies options trading.

Current Sentiment - IPA

Immunoprecise Antibodies Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in Immunoprecise Antibodies. What is your judgment towards investing in Immunoprecise Antibodies? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immunoprecise Antibodies using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Immunoprecise Antibodies Correlation against competitors. Note that the Immunoprecise Antibodies information on this page should be used as a complementary analysis to other Immunoprecise Antibodies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
96.9 M
Quarterly Revenue Growth YOY
0.066
Return On Assets
-0.19
Return On Equity
-0.43
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.